CD19-CD34t metabolically programmed CAR transduced T-cells(Medical University of South Carolina)(CD19-CD34t metabolically programmed CAR transduced T-cells(Medical University of South Carolina))

概要

基本信息

药物类型

CAR-T

别名-

靶点

CD19

作用机制

CD19抑制剂(B淋巴细胞抗原CD19抑制剂)、基因转移、T淋巴细胞替代物

治疗领域-

在研适应症-

非在研适应症-

原研机构

Medical University of South Carolina

在研机构

Medical University of South Carolina

非在研机构-

最高研发阶段临床1/2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

1

项与 CD19-CD34t metabolically programmed CAR transduced T-cells(Medical University of South Carolina) 相关的临床试验

NCT05702853 / Recruiting临床1/2期

A Phase 1b Dose Escalation Study of Metabolically Fit CD19 Chimeric Antigen Receptor (CAR) T Cells With CD34 Selection Markers in Adult Patients With Relapsed or Refractory CD19 B-Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

This is a single-center, nonrandomized, open-label dose-escalation study followed by dose-expansion of CD19- CD34t metabolically programmed CAR T-cell therapy in adult patients with relapsed or refractory CD19 B-cell non-Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

开始日期2023-11-06

申办/合作机构